{"analyses":[{"ciLowerLimit":"0.564","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.224","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.3487","paramType":"Hazard Ratio (HR)","paramValue":"0.831","statisticalMethod":"Log-rank test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.28","upperLimit":"26.32","value":"19.0"},{"groupId":"OG001","lowerLimit":"14.32","upperLimit":"26.12","value":"19.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"description":"To determine the efficacy by assessment of OS of olaparib maintenance monotherapy compared to placebo. The OS was defined as the time from the date of randomization until death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Randomised participants received orally 300 mg bd which were made up of 2 x 150 mg tablets bd with 100 mg tablets used to manage dose reductions.","id":"OG000","title":"Olaparib 300 mg Twice Daily (bd)"},{"description":"Randomised participants received placebo tablets orally 300 mg bd which were made up of 2 x 150 mg tablets bd with 100 mg tablets used to manage dose reductions.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Intention to treat (ITT): All randomised patients, Myriad confirmed Breast cancer susceptibility gene mutation (gBRCAm) subgroup.","reportingStatus":"POSTED","timeFrame":"Upto 4 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}